Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;6(4):161-172.
doi: 10.1007/s40610-020-00140-1. Epub 2020 Oct 24.

Senolytics: targeting senescent cells for age-associated diseases

Iman M A Al-Naggar  1 , George A Kuchel  1 , Ming Xu  1   2
Affiliations

Senolytics: targeting senescent cells for age-associated diseases

Iman M A Al-Naggar et al. Curr Mol Biol Rep. 2020 Dec.
No abstract available

Keywords: Aging; Cellular senescence; Healthspan; Lifespan; Senolytics.

PubMed Disclaimer

Conflict of interest statement

Competing Financial Interests Dr. Xu has financial interest related to senolytics. Patents on senolytic drugs (including PCT/US2016/041646, filed at the US Patent Office) are held by Mayo Clinic. Dr. Kuchel has nothing to disclose. Dr. Al-Naggar has nothing to disclose.

Figures

Figure 1.
Figure 1.. Senolytics Clinical Trials in Humans.
Shown are some completed, recruiting, ongoing and planned trials. Before being tested in healthy adults for delaying or alleviating aging-related diseases and syndromes, senolytics are being tested for safety and efficacy of removing senescent cells from patients with serious conditions involving senescent cell accumulation for which there are currently no other cures. These include idiopathic pulmonary fibrosis (IPF), diabetic/chronic kidney disease, tau+ Alzheimer’s disease, accelerated aging resulting from hematopoietic stem cell transplantation, frailty and osteoarthritis. Some completed Phase I trials have reported no serious adverse effects (eg, D+Q, UBX0101) and are moving on to Phase II trials. (Image created using Biorender.)
See this image and copyright information in PMC

References

    1. Miller RA. Extending life: scientific prospects and political obstacles. Milbank Q. 2002;80(1):155–74. doi:10.1111/1468-0009.00006. - DOI - PMC - PubMed
    1. Geroscience Sierra F. and the challenges of aging societies. Aging Med (Milton). 2019;2(3):132–4. doi:10.1002/agm2.12082. - DOI - PMC - PubMed
    1. Sierra F The Emergence of Geroscience as an Interdisciplinary Approach to the Enhancement of Health Span and Life Span. Cold Spring Harb Perspect Med. 2016;6(4):a025163. doi:10.1101/cshperspect.a025163. - DOI - PMC - PubMed
    1. Kaeberlein M Translational geroscience: A new paradigm for 21(st) century medicine. Transl Med Aging. 2017;1:1–4. doi:10.1016/j.tma.2017.09.004. - DOI - PMC - PubMed
    1. Melov S Geroscience approaches to increase healthspan and slow aging. F1000Res. 2016;5. doi:10.12688/f1000research.7583.1. - DOI - PMC - PubMed

LinkOut - more resources